Chronic myeloid leukemia is a clonal disease characterized by the presence of the Philadelphia chromosome and its oncogenic product, BCR-ABL, which activates multiple pathways involved in cell survival, growth promotion, and disease progression. We previously reported that in murine 
Introduction
The BCR-ABL fusion oncogene is responsible for the pathogenesis of chronic myeloid leukemia (CML) [1] , which is characterized by the premature release of leukemia cells from bone marrow as well as a substantial accumulation of those with a potential of differentiation in the blood, spleen, and bone marrow. Owing to its elevated tyrosine kinase activity, BCR-ABL activates a number of signaling pathways, including the Ras, PI3K/AKT, Janus kinase/signal transducer and activator of transcription, and NF-κB signaling pathways [1, 2] . Moreover, in various human and mouse models, hematopoietic cells expressing BCR-ABL show a growth advantage, resistance to apoptosis, and altered adhesion and homing properties.
Signal transducing adaptor protein-2 (STAP-2) is a novel adaptor molecule, which was isolated as a c-FMS interacting protein [3] . The human homolog of STAP-2 is a known substrate of breast tumor kinase (BRK) [4] . Previous work in our laboratory found that STAP-2 can associate with and influence a variety of signaling or transcriptional molecules [3, [5] [6] [7] [8] [9] , including STAT3 and STAT5 [3, 5] , and FcεRI and Toll-like receptor-mediated signals [6, 9] . Further, thymocytes and peripheral T cells from STAP-2-deficient mice show enhanced IL-2-dependent cell growth and integrin-mediated T-cell adhesion and impaired SDF-1α-induced T-cell migration [5, 7, 8] .
Because STAP-2 is expressed in a variety of tissues and cells, such as lymphocytes, macrophages, and hepatocytes, STAP-2 is also likely to function in a variety type of cells. Importantly, we identified BCR-ABL as a novel binding partner of STAP-2, and STAP-2 augmented BCR-ABL activity and activation of downstream signaling molecules, including ERK, STAT5, BCL-xL, and BCL2 [10] . We also found that STAP-2 over-expression in murine hematopoietic Ba/F3 cells confers a growth advantage in vitro and is able to induce leukemia in vivo. In addition, STAP-2 controls the migration and homing of BCR-ABL-expressing cells by influencing chemokine receptor expression levels.
In the present study, we found that chemokine receptor CCR7 influences the enhancement of follows:
Stat5a, 5'-AGGUCUUUGCCAAGUAUUATT-3'; Stat5b, 5'-GCGUGAUGGAAGUAUUGAATT-3'. Control siRNA was obtained from Qiagen (non-silencing; cat. no. 1022076).
RT-PCR and quantitative real-time PCR, Cells were harvested, total RNAs from the transfected cells were prepared by using Iso-Gen (Nippon Gene, Tokyo, Japan) and used in RT-PCR.
RT-PCR was performed using RT-PCR high -Plus-Kit (TOYOBO, Tokyo, Japan). Primers used for RT-PCR were: CXCR4:
5'-TGGAGTGTGACAGCTTGGAG-3' (antisense); Ccl19:
5'-GAAATCCCATCACCATCTTCCAGG-3' (sense),
5'-CAGTAGAGGCAGGGATGATGTTC-3' (antisense). Quantitative real-time PCR analyses of
Ccr7 as well as the control G3pdh or Actin mRNA transcripts were carried out using the assay-on-demandTM gene-specific fluorescently labeled TaqMan MGB probe in an ABI Prism 7000 sequence detection system (Applied Biosystems, Tokyo, Japan).
Western blot analysis, Western blot analyses were performed as described previously [3] . Briefly, cells were harvested and lysed in a lysis buffer (50 mM Tris-HCl, pH 7.4, 0.15 M NaCl, containing 1% NP-40, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride). The filters were then immunoblotted with each antibody. Immunoreactive proteins were visualized using an enhanced chemiluminescence detection system (Millipore; Bedford, MA).
Cell proliferation assay, The numbers of viable Ba/F3 cells after the indicated treatments were measured using a WST-8
monosodium salt] assay (Cell Counting Kit-8; Wako Pure Chemicals) [10] . Briefly, 10 µl of WST-8 solution was added to the cells in each well and incubated for 2 h. The absorbances were measured at a test wavelength of 450 nm and a reference wavelength of 595 nm using a microplate reader (Bio-Rad, Hercules, CA).
FACS Analysis
The following monoclonal antibodies were used: PE-anti-mouse CCR7 and APC-anti-human CXCR4 antibodies (eBioscience, San Diego, CA 
CXCR4 has no significant effect on BCR-ABL-dependent cell growth in Ba/F3 cells
We then tested the effect of CXCR4 expression in Ba/F3 cells on BCR-ABL/STAP-2-dependent cell growth. To this end, we transfected a human CXCR4 (hCXCR4) expression vector into Ba/F3-p210/STAP-2 cells, and established two stable clones (Ba/F3-p210/STAP-2/hCXCR4#1 and #2). Western blot analysis was used to confirm STAP-2 and BCR-ABL protein expression ( Fig. 2A) . Levels of hCXCR4 expression were also confirmed by PCR ( Fig. 2B ) and flow cytometry analysis ( Fig. 2C ) using an anti-hCXCR4 antibody. The reduced level of endogenous CXCR4 expression was completely nullified by the exogenous hCXCR4 expression. As shown in (Fig. 3F) . Therefore, CCR7
influences cell growth and/or migration of p210/STAP-2-expressing Ba/F3 cells.
4. Ba/F3-p210/STAP-2 cells express the CCR7 ligands
CCR7 is a cell surface protein, which transduces signals for cell proliferation and migration in response to its ligands, CCL19 and CCL21. To explain the involvement of CCR7 expression in the observations described above, we speculated that Ba/F3-p210/STAP-2 cells express CCR7 ligands.
As shown in Fig. 3G , PCR analysis could not detect CCL19 or CCL21 mRNAs in Ba/F3-p210 cells, but their expression was clearly observed when Ba/F3 cells were transfected with both BCR-ABL and STAP-2 (Fig. 3G ). In parallel to the level of CCL19 mRNA expression, the proliferation of Ba/F3-p210/STAP-2 cells, but not of Ba/F3-p210 cells, was enhanced in a dose-dependent manner (Fig. 3H) . Therefore, Ba/F3-p210/STAP-2 cells produce and respond to CCL19 and CCL21 in an autocrine manner.
5. The MAPK/ERK pathway is involved in CCR7 expression in BCR-ABL/STAP-2-expressing Ba/F3 cells
To confirm which signaling pathway is involved in CCR7 expression and growth in Ba/F3-BCR-ABL/STAP-2 cells, we examined the effect of STAT5 knockdown or of pharmacological inhibition of the AKT or MAPK/ERK pathway. As shown in Fig. 4A and B, neither STAT5 knockdown nor treatment with A6730, an AKT inhibitor, produced a significant effect on CCR7 mRNA levels in Ba/F3-p210/STAP-2 cells. However, treatment of Ba/F3-p210/STAP-2 cells with U0126, a MAPK/ERK inhibitor, produced a significant inhibitory effect on CCR7 mRNA expression (Fig. 4C) . Therefore, the MAPK/ERK pathway is involved in CCR7 expression in Ba/F3-p210/STAP-2 cells.
We also examined the effect of STAT5 knockdown or the two pharmacological inhibitors on Ba/F3-p210/STAP-2 cell growth. STAT5 knockdown (Fig. 4A ) and pharmacological inhibition of the AKT (Fig. 4B) or MAPK/ERK ( CCR7 expression is crucial for thymocyte trafficking across the corticomedullary junction in the thymus and for lymph node homing of naive T cells [17, 18] . CCR7 expression in CD4 + CD8
+ T cells and thymocytes requires both ERK-and Ca

2+
-dependent signaling pathways [19] . In human breast cancer cells, the involvement of AKT-mediated Sp1 activation in prostaglandin E2-induced CCR7 expression has been reported [20] . Here, we showed that STAP-2-mediated CCR7 expression requires the MAPK/ERK signaling pathway in BaF/3-p210 cells. AKT phosphorylates Sp1 at S42, T679, and S698 [20] . ERK phosphorylates T453 and T739 of Sp1 to increase its transcriptional activities. C-Jun NH 2 -terminal kinase 1 phosphorylates SP1 at T278 and T739, which controls its degradation [21] . In 
